Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Recent News

DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma
KEYNOTE-629: Pembrolizumab in Metastatic Cutaneous Squamous Cell Carcinoma
Novel First-in-Class Agent Shows Activity in High-Grade Serous Ovarian Cancer
Front-Line Immunotherapy for Locally Advanced Basal Cell Carcinoma: Case Studies
FDA Accepts Two Applications for Pembrolizumab in Triple-Negative Breast Cancer
Combined REMARRY and PURSUIT Trials to Assess Metastatic Colorectal Cancer
Vaccinating Against Pneumonia in Patients With Myeloma
Survival Update With Bevacizumab Plus Erlotinib in Certain Patients With NSCLC
Second-Line Treatment Alternatives for Metastatic Colorectal Cancer
Subgroup Analysis of Isatuximab-Based Therapy for Resistant Myeloma
ESMO World GI: Pembrolizumab Plus Ibrutinib Under Study in Metastatic Colorectal Cancer
Adding Platinum Doublet to Immunotherapy Combination in Advanced Lung Cancer
The Gut Microbiome's Response to Immunotherapy for Lung Cancer
AACR II: Antibody-Drug Conjugate Targets CLDN6/9 in Epithelial Ovarian Cancer
EHA25 Virtual: Adding Elotuzumab to Treatment Regimen in Newly Diagnosed Myeloma
3-Year TRAIN-2 Update on Neoadjuvant Therapy for HER2-Positive Breast Cancer
EHA25 Virtual: Quality of Life With Duvelisib Versus Ofatumumab in CLL
Health-Related Quality of Life With Cemiplimab for Skin Cancer
Does Anaplastic Thyroid Carcinoma Respond to PD-1 Blockade?
EHA25 Virtual: Does Administration Sequence of Ibrutinib/Obinutuzumab in CLL Affect Toxicity?
AACR II: Early Results With Dual Inhibitors of IGF and CDK4/6 in Lung Cancer
AACR II: Adding Interferon-Gamma to Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer
Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
Immune-Mediated Adverse Events With Concomitant Radiotherapy and Immunotherapy
Interim Results of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC
Combining IL-7 With Pembrolizumab in Metastatic Triple-Negative Breast Cancer
EHA25 Virtual: Adding Isatuximab to Front-Line Standard of Care in High-Risk Myeloma
AACR II: Flat Dosing of Nivolumab in Patients Previously Treated for NSCLC
Subcutaneous Combination Therapy Approved by FDA for HER2-Positive Breast Cancer
HER2-Targeted Therapy With Trastuzumab Deruxtecan in Lung Cancer
Pembrolizumab Approved by FDA for Cutaneous Squamous Cell Carcinoma
ASCO20: 3-Year Update on Nivolumab Plus Ipilimumab as First-Line Treatment of NSCLC
ASCO20: Tucatinib Combination Therapy for Breast Cancer With Brain Metastases
EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma
ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL
ASCO20: Update on BCMA-Directed CAR-T Cell Therapy for Resistant Myeloma
ASCO20: Tiragolumab Plus Atezolizumab for PD-L1–Selected NSCLC
First-in-Class Immunotherapy With Azacitidine Under Study in AML
ASCO20: Can Radioiodine Plus Durvalumab Improve Outcomes in Resistant Thyroid Cancer?
ASCO20: KEYNOTE-355 Trial of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ASCO20: Antibody-Drug Conjugate Active in CEACAM5-Expressing Nonsquamous NSCLC
ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL
EHA25 Virtual: Adding Isatuximab to Carfilzomib and Dexamethasone in Resistant Myeloma
Biologic Therapies for Patient With Both Lung Cancer and Multiple Myeloma
ASCO20: Does Adding Trastuzumab to Radiotherapy Decrease Recurrence of Breast Cancer?
ASCO20: Update on Orvacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
ASCO20: Longer-Term Follow-Up Supports Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
ASCO20: Autologous Tumor Immunotherapy Plus Atezolizumab in Recurrent Ovarian Cancer
ASCO20: Trastuzumab Deruxtecan in HER2-Expressing Metastatic Colorectal Cancer
ASCO20: Cabozantinib Plus Atezolizumab for Castration-Resistant Prostate Cancer
EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL
ASCO20: Antibody-Drug Conjugate Plus Bevacizumab in Platinum-Agnostic Ovarian Cancer
ASCO20: Treating Anaplastic Thyroid Cancer Based on Driver Mutations


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.